Compare Merck & Co., Inc. (MRK) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Twilio Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Twilio Inc trades at $195.3 (market cap $31.15B). The key difference: Merck & Co., Inc. is far larger — about 9.9× Twilio Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| MRK | TWLO | |
|---|---|---|
Market Cap | $307.25B | $31.15B |
Sector | Health | Technology |
52-Week High | $129.52 | $236.64 |
52-Week Low | $77.60 | $92.44 |
Enterprise Value | $350.66B | $29.87B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Twilio (TWLO) trades at $196.22, down 5.11% in the last session, as investors await Q2 2026 earnings on August 6. The stock shows a bullish technical signal with strong moving average support and oversold RSI conditions. Fundamentally, the company has delivered three consecutive earnings beats with revenue growth from $3.8B in 2022 to $5.1B in 2025, though profitability remains modest with a 1.96% net margin. Operating cash flow improved significantly to $1.0B in 2025, indicating stronger business execution.
The outlook remains positive with 77% analyst buy ratings and a $227.64 consensus price target representing 16% upside. Key opportunities include AI-powered communication growth and margin expansion, while risks center on high valuation multiples (P/E 311) and competitive pressures. The upcoming earnings report will be critical for validating the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
